ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Review
- Bruton's tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.Blood cancer journal · 2025Article
- The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment.Nature reviews. Cancer · 2023Review
- eIF4A1-dependent mRNAs employ purine-rich 5'UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation.Nucleic acids research · 2023Article
- Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers.Frontiers in molecular biosciences · 2023Review
- Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.Molecular medicine (Cambridge, Mass.) · 2022Article
- B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.Cellular signalling · 2022Article
- Translation initiation and its relevance in colorectal cancer.The FEBS journal · 2021Review
- Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action.Journal of medicinal chemistry · 2021Article
- Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.Scientific reports · 2021Article
- Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.Cell reports · 2021Article
- Molecular Dynamics Simulations Identify Tractable Lead-like Phenyl-Piperazine Scaffolds as eIF4A1 ATP-competitive Inhibitors.ACS omega · 2021Article
- Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.Cellular and molecular life sciences : CMLS · 2021Article
- Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.Microorganisms · 2021Review
- Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers.Frontiers in cell and developmental biology · 2021Review
- Marine Bioactive Compounds againstAntibiotics (Basel, Switzerland) · 2020Review
- Eukaryotic translation initiation factors as promising targets in cancer therapy.Cell communication and signaling : CCS · 2020Review
- Targeting Protein Synthesis in Colorectal Cancer.Cancers · 2020Review
- A comparative study of small molecules targeting eIF4A.RNA (New York, N.Y.) · 2020Article
- Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.Exploration of targeted anti-tumor therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 3 countries.
Tara L PetersSheila and David Fuente Graduate Program in Cancer Biology, University of Miami, Miami, Florida.
Joseph TillotsonCollege of Pharmacy, University of Arizona, Tucson, Arizona.
Alison M YeomansSomers Cancer Science Building, University of Southampton, Southampton, United Kingdom.
Sarah WilmoreUniversity of Southampton, Southampton, United Kingdom.
Elizabeth LemmCancer Research UK Centre, University of Southampton, Southampton, United Kingdom.
Carlos Jiménez-RomeroMolecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico.
Luis A AmadorMolecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico.
Lingxiao LiSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Amit D AminSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Praechompoo PongtornpipatThe University of Arizona Comprehensive Cancer Center, Tucson, Arizona.
Christopher J ZerioCollege of Pharmacy, University of Arizona, Tucson, Arizona.
Andrew J AmbroseCollege of Pharmacy, University of Arizona, Tucson, Arizona.
Gillian Paine-MurrietaThe University of Arizona Comprehensive Cancer Center, Tucson, Arizona.
Patricia GreningerCenter for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Francisco VegaSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Cyril H BenesCenter for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Graham PackhamCancer Research UK Centre, University of Southampton, Southampton, United Kingdom.
Abimael D RodríguezMolecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico.
Eli ChapmanCollege of Pharmacy, University of Arizona, Tucson, Arizona. jschatz@med.miami.edu chapman@pharmacy.arizona.edu.
Jonathan H SchatzSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida. jschatz@med.miami.edu chapman@pharmacy.arizona.edu.ORCID 0000-0003-1842-228X
University of Arizona · USUniversity of Miami · USUniversity of Puerto Rico System · PRCenter for Cancer Research · USNIHR Southampton Biomedical Research Centre · GBUniversity of Southampton · GBUniversity of Miami Health System · US
Funding
VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2MCHEMISTRY-BIOLOGY INTERFACE TRAINING PROGRAMT32GM008804 · NIGMS · UNIVERSITY OF ARIZONA · PI MONTFORT, WILLIAM R. · 2003 to 2023
$3.9MA New Treatment Paradigm for ALK-Driven Cancers Exploiting Oncogene OverdoseR01CA190696 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SCHATZ, JONATHAN H · 2014 to 2018
$1.5MNew Leads Against Cancer and Infectious Diseases from Puerto Rican Reef SpeciesSC1GM086271 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI RODRIGUEZ, ABIMAEL D · 2010 to 2013
$1.2MDeveloping a novel platform for rapid identification of drug targets and anti-targetsR41TR002293 · NCATS · TRUVITECH, LLC · PI AL-ALI, HASSAN, SCHATZ, JONATHAN H · 2018 to 2018
$225kCancer Research UK 23669NCATS NIH HHS R41 TR002293NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA190696NIGMS NIH HHS SC1 GM086271NIGMS NIH HHS T32 GM008804Wellcome Trust
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adenosine TriphosphatasesAnimalsApoptosisAquatic OrganismsBiological ProductsCell Line, TumorCell ProliferationEukaryotic Initiation Factor-4AFibroblastsHeterograftsHumansMiceModels, MolecularNeoplasmsProtein BiosynthesisProteomicsAdenosine TriphosphatasesBiological ProductselatolEukaryotic Initiation Factor-4ASpiro Compounds
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.